▁clin ical ▁tri als . ▁ ▁Comp ounds ▁which ▁increased ▁SM N 2 ▁activity ▁in ▁vit ro ▁but ▁did ▁not ▁make ▁it ▁to ▁the ▁clin ical ▁stage ▁include ▁growth ▁h orm one , ▁various ▁hist one ▁de ac et yl ase ▁in hib itors , ▁ben z am ide ▁M 3 4 4 , ▁hydro x am ic ▁ac ids ▁( CB HA , ▁S B HA , ▁ent in ost at , ▁pan ob in ost at , ▁tr ich ost atin ▁A , ▁vor in ost at ), ▁pro la ct in ▁as ▁well ▁as ▁natural ▁poly phen ol ▁comp ounds ▁like ▁res ver at rol ▁and ▁cur c umin . ▁C ele co x ib , ▁a ▁p 3 8 ▁path way ▁activ ator , ▁is ▁sometimes ▁used ▁off - label ▁by ▁people ▁with ▁S MA ▁based ▁on ▁a ▁single ▁animal ▁study ▁but ▁such ▁use ▁is ▁not ▁back ed ▁by ▁clin ical - stage ▁research . ▁ ▁SM N ▁stabil isation ▁ ▁SM N ▁stabil isation ▁a ims ▁at ▁stabil ising ▁the ▁SM N Δ 7 ▁protein , ▁the ▁short - l ived ▁defect ive ▁protein ▁c oded ▁by ▁the ▁SM N 2 ▁gene , ▁so ▁that ▁it ▁is ▁able ▁to ▁sust ain ▁neur onal ▁cells . ▁ ▁No ▁comp ounds ▁have ▁been ▁taken ▁forward ▁to ▁the ▁clin ical ▁stage . ▁A min og ly cos ides ▁showed ▁cap ability ▁to ▁increase ▁SM N ▁protein ▁avail ability ▁in ▁two ▁studies . ▁Ind opro fen ▁offered ▁some ▁promise ▁in ▁vit ro